The original disclosure in Japanese was released on February 13, 2020 at 15:30 (GMT+9)

Consolidated Financial Statements for the Third Quarter Ended December 31, 2019
FY2020 (April 1, 2019 - March 31, 2020) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (1st section)
Code number: 2531
URL: https://www.takara.co.jp/
Company representative: Mutsumi Kimura, President
Contact: Takuya Kakemi, General Manager of Investor Relations Dept.
TEL : (075)241-5124
Quarterly statement filing date (as planned): February 14, 2020

Notes:
1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the nine months ended December 31, 2019 (April 1, 2019 - December 31, 2019)

(1) Consolidated Operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Nine months ended December 31, 2019		Nine months ended December 31, 2018	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	212,172	0.7	210,622	3.1
Operating income (loss)	12,836	(14.5)	15,015	10.4
Ordinary income (loss)	13,290	(13.8)	15,420	10.3
Net income (loss) attributable to owners of the parent	8,300	(7.3)	8,952	(13.9)
Net income (loss) per share (Yen)	41.61		44.85	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income (loss)	6,406	(5.9)	6,807	(54.2)

(2) Consolidated Financial position

	As of December 31, 2019	As of March 31, 2019
	(Millions of yen)	(Millions of yen)
Total assets	287,676	287,106
Net assets	180,804	179,795
Equity ratio (%)	51.8	51.6
(Reference) Equity	149,065	148,197

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2019	Year ending March 31, 2020	Year ending March 31, 2020 (Forecast)
First quarter end	-	-	
Second quarter end	-	-	
Third quarter end	-	-	
Year end	18.00		20.00
Annual	18.00		20.00

Note: Correction of dividend forecast from the most recent dividend forecast : No

3. Forecast for the year ending March 31, 2020 (April 1, 2019 - March 31, 2020)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2020	
	(Millions of yen)	(%)
Net sales	280,000	0.9
Operating income (loss)	15,300	(14.1)
Ordinary income (loss)	15,700	(14.5)
Net income (loss) attributable to owners of the parent	8,600	(17.4)
Net income per share (Yen)	43.20	

Note: Correction of financial forecast from the most recent financial forecast : Yes

4. Others

(1) Material changes in subsidiaries during this period
(Changes in specified subsidiaries that caused a change in the scope of consolidation): No

(2) Accounting procedures specific to quarterly consolidated financial statements: No

(3) Changes in accounting policies, accounting estimates and retrospective restatement

1) Changes based on revisions of accounting standard: Yes
2) Changes other than ones based on revisions of accounting standard: No
3) Changes in accounting estimates: No
4) Restatement: No

(4) Number of outstanding shares (common stock)

1) Number of outstanding shares at the end of each period (Treasury stocks are included):

As of December 31, 2019	201,699,743 shares
As of March 31, 2019	201,699,743 shares

2) Number of treasury stocks at the end of each period:

As of December 31, 2019	3,577,758 shares
As of March 31, 2019	2,069,706 shares

3) Average number of outstanding shares in each period:

Nine months ended December 31, 2019	199,495,658 shares
Nine months ended December 31, 2018	199,630,283 shares

Contents of the attached document

1. Qualitative Information for the Nine Months Ended December 31, 2019……. 2

(1) Consolidated Financial Results……... 2

(2) Consolidated Financial Position…….. 3

(3) Qualitative Information Regarding Consolidated Forecasts……... 4

2. Consolidated Financial Statements and Important Notes……... 5

(1) Consolidated Balance Sheets…….. 5

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income……. 7

(Consolidated Statements of Income)……..... 7
(For the Nine Months Ended December 31, 2019 and 2018)

(Consolidated Statements of Comprehensive Income)…….. 8
(For the Nine Months Ended December 31, 2019 and 2018)

(3) Notes on Consolidated Financial Statements ……..... 9

(Notes on Premise of Going Concern) …….. 9

(Notes on Material Changes in Shareholders' Equity) ……. 9

(Changes in Accounting Policies) ……. 9

(Segment Information) …….. 9

(Significant Subsequent Events)…… 10

○Supplement for the Consolidated Financial Statements

1. Qualitative Information for the Nine Months Ended December 31, 2019

(1) Consolidated Financial Results

In the nine months ended December 31, 2019, although some weakness persisted, primarily for exports, the Japanese economy maintained a moderate recovery backed by continued improvements in the employment and income environment. While the moderate recovery overall is expected to continue overseas, the global economic outlook remains uncertain, mainly due to such factors as the developments around trade issues, the impact of the U.K. withdrawal from the EU, and the slowdown in the Chinese economy.

Under these economic circumstances, under the Takara Group Medium-Term Management Plan FY2020, which is the last step towards achieving its long-term Takara Group Vision 2020, the Company is aiming to build up a great number of fields in which it can beat competitors and establish a balanced business foundation able to grow revenues significantly, no matter what environmental changes occur, by further increasing the overseas sales ratio together with having a full product line-up and many products with a competitive edge, both in Japan and overseas.

As a result, in the nine months ended December 31, 2019, net sales were up 0.7% year on year to ¥212,172 million. Gross profit fell 1.1% year on year to ¥82,004 million. Operating income decreased by 14.5% year on year to ¥12,836 million while ordinary income fell 13.8% year on year to ¥13,290 million. Net income attributable to owners of the parent decreased by 7.3% year on year to ¥8,300 million.

Results by business segment were as follows.

[Takara Shuzo]

For alcoholic beverages, in the nine months ended December 31, 2019, while sales of light-alcohol refreshers remained robust, sales of shochu and sake fell, and sales of alcoholic beverages overall declined.

In the seasonings, sales increased as sales of mirin and cooking sake grew. Sales of raw alcohol and other products were up as sales of raw alcohol for alcoholic beverages remained strong.

As a result, net sales for the Takara Shuzo Group fell 0.1% year on year to ¥118,897 million. Cost of sales increased by 0.9% year on year to ¥71,578 million. Consequently, gross profit fell 1.6% year on year to ¥47,318 million. SG&A expenses were up by 2.3% year on year to ¥42,334 million, due to increases in promotion expenses and other expenses. Accordingly, the Takara Shuzo Group recorded operating income down 25.4% year on year to ¥4,983 million.

[Takara Shuzo International Group]

In the nine months ended December 31, 2019, sales for the Japanese Food Wholesale Business in overseas markets remained robust for Mutual Trading Co., Inc. (U.S.) and other companies. Sales of products such as whiskey also increased in the Overseas Alcoholic Beverage Business. As a result, net sales for the Takara Shozo International Group increased by 6.4% to ¥60,461 million.

Cost of sales increased by 7.5% year on year to ¥43,194 million. Consequently, gross profit rose by 3.7% year on year to ¥17,266 million. SG&A expenses were up by 11.5% year on year to ¥14,953 million due mainly to increases in personnel and transportation expenses. Accordingly, the Takara Shuzo International Group recorded operating income down 28.4% to ¥2,313 million.

[Takara Bio Group]

Net sales for the nine months ended December 31, 2019 were down by 5.1% year on year to ¥24,558 million due to a decrease in sales of scientific instruments and the impact from the transfer of both the functional food and the mushroom businesses during the previous fiscal year although sales of mainstay research reagents and contract research services increased. Cost of sales fell 10.8% year on year to ¥9,767 million, due to a lower cost rate with changes in the structure of sales for each product, and gross profit decreased 1.0% year on year to ¥14,791 million.

SG&A expenses decreased by 5.2% year on year to ¥10,911 million due to a decrease in research and development expenses and other factors. Accordingly, operating income increased by 13.0% year on year to ¥3,879 million.

[Other]

Net sales of the Other segment for the nine months ended December 31, 2019 declined 3.7% to ¥24,644 million as Takara Healthcare Inc. was excluded from the scope of consolidation during the previous fiscal year accompanying the sale of shares in that company although sales in the logistics business and other businesses increased.

Cost of sales declined by 1.1% year on year to ¥21,393 million. Consequently, gross profit decreased by 18.1% year on year to ¥3,251 million. SG&A expenses fell by 33.8% year on year to ¥1,535 million due mainly to decreases in personnel and advertisement expenses. As a result, operating income increased by 3.9% year on year to ¥1,716 million.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2018, to December 31, 2018)	Period under Review (From April 1, 2019, to December 31, 2019)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo			
Shochu	41,186	38,026	92.3
Sake	17,524	16,860	96.2
Light-alcohol refreshers	29,742	32,603	109.6
Other alcoholic beverages	5,051	4,970	98.4
Alcoholic beverages total	93,505	92,460	98.9
Hon Mirin	11,032	11,238	101.9
Other seasonings	7,779	8,222	105.7
Seasonings total	18,811	19,461	103.5
Raw alcohol, etc	6,683	6,975	104.4
Total	119,001	118,897	99.9
Takara Shuzo International Group			
Overseas Alcoholic Beverages Business	7,616	8,010	105.2
Japanese Food Wholesales Business in overseas markets	50,591	53,881	106.5
Other	48	190	393.6
Elimination of intraGroup transaction on consolidation	(1,413)	(1,622)	—
Total	56,843	60,461	106.4
Takara Bio Group	25,888	24,558	94.9
Reported segment total	201,732	203,917	101.1
Other	25,593	24,644	96.3
Segment total	227,326	228,562	100.5
Sales not allocated to business segments and intersegment transactions	(16,703)	(16,389)	—
Total	210,622	212,172	100.7

Notes: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position

As of December 31, 2019, current assets were ¥171,418 million, a decrease of ¥3,592 million compared with that at the end of the previous fiscal year. This was primarily due to decreases in securities of ¥11,162 million and cash and deposits of ¥3,977 million and an increase in notes and accounts receivable-trade of ¥8,716 million.

Noncurrent assets were ¥116,257 million, an increase of ¥4,162 million compared with that at the end of the previous fiscal year. This was primarily due to an increase of ¥6,357 million in property, plant and equipment and a decrease of ¥1,795 million in intangible assets.

As a result, total assets were ¥287,676 million, an increase of ¥569 million compared with that at the end of the previous fiscal year.

As of December 31, 2019, current liabilities were ¥61,034 million, an increase of ¥3,212 million compared with that at the end of the previous fiscal year. This was primarily due to increases of ¥5,000 million in current portion of bonds due to transfer from noncurrent liabilities, ¥1,526 million in accrued alcohol tax, and ¥2,524 million in Other, which includes accounts payable. There was also a decrease of ¥5,163 million in short-term loans payable.

Noncurrent liabilities were ¥45,836 million, a decrease of ¥3,652 million compared with that at the end of the previous fiscal year. This was primarily due to a decrease in bonds of ¥5,000 million.

As a result, total liabilities were ¥106,871 million, a decrease of ¥440 million compared with that at the end of the previous fiscal year.

As of December 31, 2019, total net assets were ¥180,804 million, an increase of ¥1,009 million compared with that at the end of the previous fiscal year. This was primarily due to an increase in retained earnings of ¥4,782 million and a decrease in foreign currency translation adjustment of ¥3,074 million.

As a result, the equity ratio totaled 51.8%, compared with 51.6% at the end of the previous fiscal year.

(3) Qualitative Information Regarding Consolidated Forecasts

The Company has revised the full-year consolidated results forecasts published on November 12, 2019 in view of the consolidated business results in the nine months ended December 31, 2019 and recent circumstances.

The Company has revised the full-year forecast for net sales down by ¥4,000 million from the previously published forecast as net sales at Takara Shuzo for the third quarter (October 1, 2019 to December 31, 2019), which is the period of peak demand, underperformed the plan among other factors.

In terms of profit, the Company has revised the forecasts for operating income and ordinary income down by ¥2,200 million and ¥2,300 million respectively as in addition to underperforming the plan for net sales at Takara Shuzo, there have been hikes in the price of raw materials and increases in transport and SG&A expenses plus continued increases in procurement costs and hikes in transport and personnel expenses due to exchange rate fluctuations at the Takara Shuzo International Group.

Net income attributable to owners of the parent has been revised down by ¥1,800 million from the previously published forecast due to the expectation of an increase in losses related to noncurrent assets at the Takara Bio Group in addition to the aforementioned factors.

The details of the revised consolidated results forecasts are on page 8/8 “Supplement for the Consolidated Financial Statements.”

(Full-Year Consolidated Results Forecasts)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of the parent	Net income per share
Previous forecast (A) (published November 12, 2019)	(Millions of yen) 284,000	(Millions of yen) 17,500	(Millions of yen) 18,000	(Millions of yen) 10,400	(Yen) 52.10
Revised forecast (B)	280,000	15,300	15,700	8,600	43.20
Difference (B – A)	(4,000)	(2,200)	(2,300)	(1,800)	―
Difference (%)	(1.4)	(12.6)	(12.8)	(17.3)	―
Reference: Business results for previous fiscal year (Ended March 31, 2019)	277,443	17,804	18,359	10,411	52.15

* Previous exchange rate forecasts: USD1 = JPY108.30, EUR1 = JPY121.30, GBP1 = JPY134.50
Current exchange rate forecasts: USD1 = JPY109.03, EUR1 = JPY122.03, GBP1 = JPY139.19

2. Consolidated Financial Statements and Primary Notes

(1) Consolidated Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2019	As of Dec. 31, 2019
Assets		
Current assets		
Cash and deposits	49,415	45,438
Notes and accounts receivable-trade	59,780	68,497
Securities	16,089	4,927
Merchandise and finished goods	40,600	41,212
Work in process	1,341	1,610
Raw materials and supplies	4,093	5,030
Other	4,006	5,016
Allowance for doubtful accounts	(315)	(314)
Total current assets	175,011	171,418
Noncurrent assets		
Property, plant and equipment	60,576	66,934
Intangible assets		
Goodwill	12,400	11,263
Other	7,514	6,855
Total intangible assets	19,914	18,118
Investments and other assets		
Investment securities	26,143	26,797
Other	5,520	4,470
Allowance for doubtful accounts	(60)	(64)
Total investments and other assets	31,603	31,204
Total noncurrent assets	112,094	116,257
Total assets	287,106	287,676

(Millions of Yen)

	As of Mar. 31, 2019	As of Dec. 31, 2019
Liabilities		
Current liabilities		
Notes and accounts payable-trade	16,374	16,971
Short-term loans payable	9,960	4,796
Current portion of bonds	-	5,000
Accrued alcohol tax	10,224	11,751
Accrued expenses	5,809	5,455
Income taxes payable	1,879	1,613
Provision	4,681	4,029
Other	8,891	11,416
Total current liabilities	57,822	61,034
Noncurrent liabilities		
Bonds payable	25,000	20,000
Long-term loans payable	5,415	5,454
Net defined benefit liability	8,757	8,775
Long-term deposits received	5,337	5,331
Other	4,977	6,275
Total noncurrent liabilities	49,489	45,836
Total liabilities	107,311	106,871
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	2,417	2,417
Retained earnings	124,788	129,571
Treasury stock	(1,368)	(2,950)
Total shareholders' equity	139,064	142,263
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	9,814	10,599
Deferred gains or losses on hedges	114	101
Foreign currency translation adjustment	(196)	(3,270)
Remeasurements of defined benefit plans	(599)	(628)
Total accumulated other comprehensive income	9,133	6,801
Noncontrolling interests	31,597	31,739
Total net assets	179,795	180,804
Total liabilities and net assets	287,106	287,676

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

(Consolidated Statements of Income)
(For the Nine Months Ended December 31, 2019 and 2018)

(Millions of Yen)

	FY2019 (Apr. 1, 2018 – Dec. 31, 2018)	FY2020 (Apr. 1, 2019 – Dec. 31, 2019)
Net sales	210,622	212,172
Cost of sales	127,706	130,168
Gross profit	82,915	82,004
Selling, general and administrative expenses	67,900	69,167
Operating income	15,015	12,836
Non-operating income		
Dividends income	553	585
Other	512	697
Total non-operating income	1,065	1,283
Non-operating expenses		
Interest expenses	276	303
Foreign exchange losses	88	209
Other	296	315
Total non-operating expenses	661	829
Ordinary income	15,420	13,290
Extraordinary income		
Gain on sales of investment securities	0	1,130
Insurance claim income	71	-
Other	9	163
Total extraordinary income	81	1,294
Extraordinary loss		
Loss on sales and retirement of non-current assets	128	233
Impairment loss	696	-
Provision for environmental measures	-	415
Other	249	139
Total extraordinary losses	1,075	787
Income before income taxes	14,426	13,797
Income taxes-current	4,627	4,019
Income taxes-deferred	(310)	305
Total income taxes	4,316	4,324
Net income	10,110	9,473
Net income attributable to the noncontrolling interest	1,157	1,172
Net income attributable to owners of the parent	8,952	8,300

(Consolidated Statements of Comprehensive Income)
(For the Nine Months Ended December 31, 2019 and 2018)

(Millions of Yen)

	FY2019 (Apr. 1, 2018 – Dec. 31, 2018)	FY2020 (Apr. 1, 2019 – Dec. 31, 2019)
Net income	10,110	9,473
Other comprehensive income		
Valuation difference on available-for-sale securities	(2,641)	785
Deferred gains or losses on hedges	214	(13)
Foreign currency translation adjustment	(875)	(3,820)
Remeasurements of defined benefit plans	(0)	(18)
Total other comprehensive income	(3,302)	(3,067)
Comprehensive income	6,807	6,406
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	5,931	5,969
Comprehensive income attributable to noncontrolling interest	875	436

(3) Notes on Consolidated Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Changes in Accounting Policies)

Overseas subsidiaries that apply U.S. GAAP adopted ASU No. 2014-09 Revenue from Contracts with Customers ("ASU No. 2014-09") effective from the beginning of the first quarter of the fiscal year. The method of recognizing the cumulative impact due to the adoption of the standard on the commencement date of adoption, which is permitted as an interim measure, was employed for the adoption of ASU No. 2014-09.

Accompanying this, revenue is recognized at the time of transfer to the customer of the promised goods or services in an amount that reflects the consideration that the entity expects to be entitled to in exchange for those goods and services.

The impact on the Consolidated Quarterly Financial Statements from the adoption of this accounting standard is immaterial.

Overseas subsidiaries that apply International Financial Reporting Standards (IFRS) adopted IFRS 16 Leases ("IFRS 16") effective from the beginning of the first quarter of the fiscal year. The method of recognizing the cumulative impact due to the adoption of the standard on the commencement date of adoption, which is permitted as an interim measure, was employed for the adoption of IFRS 16.

Accompanying this, as a rule, the lessee recognizes all leases as assets and liabilities on the commencement date of adoption.

The impact on the Consolidated Quarterly Financial Statements from the adoption of this accounting standard is immaterial.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2018, to December 31, 2018)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	118,520	56,625	25,480	200,626	9,996	210,622	0	210,622
Intersegment	481	217	407	1,106	15,597	16,703	(16,703)	—
Total	119,001	56,843	25,888	201,732	25,593	227,326	(16,703)	210,622
Segment income (loss)	6,683	3,230	3,432	13,346	1,651	14,997	18	15,015

Notes: 1. Other includes business segments that are not part of reported segments, such as the Company's real estate rental business and the transportation business of domestic Group companies among others.

2. Details of adjustment amounts are as follows.
   (1) Net sales to external customers are income from business contracting recorded at the Company.
   (2) Segment income (loss) comprises intersegment eliminations of ¥55 million and loss of the Company not allocated to business segments of ¥ 37 million.

3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

(Significant Impairment Losses Concerning Noncurrent Asset)

Impairment losses relating to business assets which are expected to be idle and assets relating to a planned business transfer have been recorded in the Takara Bio Group segment as extraordinary loss.

The amount of impairment losses recorded was ¥696 million in the nine months ended December 31, 2018.

II Period under Review (From April 1, 2019, to December 31, 2019)

1. Net Sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	118,411	60,214	24,557	203,183	8,984	212,167	5	212,172
Intersegment	485	246	1	733	15,660	16,394	(16,394)	—
Total	118,897	60,461	24,558	203,917	24,644	228,562	(16,389)	212,172
Segment income	4,983	2,313	3,879	11,176	1,716	12,892	(56)	12,836

Notes: 1. Other includes business segments that are not part of reported segments, such as the Company's real estate rental business and the transportation business of domestic Group companies among others.

2. Details of adjustment amounts are as follows.

(1) Net sales to external customers are income from business contracting recorded at the Company.

(2) Segment income (loss) comprises intersegment eliminations of ¥36 million and loss of the Company not allocated to business segments of ¥ 92 million.

3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

(Significant Subsequent Events)

(Significant Facility investment)

The Company has resolved a facility investment in Takara Bio USA, Inc. (TBUSA), a consolidated subsidiary company at the board of directors' meeting held on January 23, 2020.

1. Reason for facility investment

The reason is that TBUSA utilizes as a new facility. Also, TBUSA plans for relocation at the time of terminating the agreement of the current lease set in August 2021.

2. Outline of facility investment

(1) Location — Bay area, California, USA

(2) Purpose — Land, building and interior construction located newly

(3) Investment amount — About 76 million U.S. dollars

3. Installation time of equipment

2020 — Land and building obtained

2021 — Planned for completion of interior construction

2021 — Planned for relocation

4. Significant impact on marketing and productivity

No impact on the current consolidated fiscal year.

(Acquisition of Treasury Stock and the Cancellation of Treasury Stock)

The meeting of the Company's Board of Directors held on November 12, 2019, approved the acquisition of treasury stock based on the provisions for Article 156 of the Companies Act described in Article 165 (3) of the same act and the cancellation of treasury stock based on the provision of Article 178 of the Companies Act.

1. Reasons for the acquisition and cancellation of treasury stock

In accordance with the financial policy stated in the Takara Group Medium-Term Management Plan FY2020, which is to"maintain a strong balance sheet and make growth-oriented investments while also improving our ROE and achieving proper stock price levels by providing appropriate shareholder returns," treasury stock is to be acquired to promote the efficient use of capital in addition to raising shareholder value per share and enhancing the return of profit to shareholders.

In addition, the Company will cancel its treasury stock in accordance with the Company's policy on ownership of treasury stock.

2. Details of acquisition of treasury stock

(1) Classification of stock to be acquired	Common stock of the Company
(2) Number of shares to be acquired	2.0 million shares (upper limit) (1.00% of total number of shares issued and outstanding (excluding treasury stock))
(3) Total cost of acquisition	2.0 billion yen (upper limit)
(4) Period of acquisition	November 18, 2019 to January 17, 2020
(5) Method of acquisition	Open market purchase through the Tokyo Stock Exchange

3. Details of cancellation of treasury stock

(1) Classification of stock to be cancelled	Common stock of the Company
(2) Number of shares to be cancelled	2.0 million shares (0.99% of total number of shares issued and outstanding before cancellation)
(3) Scheduled cancellation date	January 31, 2020

As resolved by the above of the Company's Board of Directors, the Company acquired and cancelled treasury stock as outlined below.

1. Acquisition of treasury stock

(1) Classification of stock to be acquired	Common stock of the Company
(2) Number of shares acquired	1,925,300shares
(3) Total cost of acquisition	¥1,999,916,400
(4) Period of acquisition	November 18, 2019 to January 9, 2020
(5) Method of acquisition	Open market purchase through the Tokyo Stock Exchange

2. Cancellation of treasury stock

(1) Classification of stock cancelled	Common stock of the Company
(2) Number of shares cancelled	2,000,000 shares
(3) Date of cancellation	January 31, 2020

2020年3月期
第3四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Third Quarter Ended December 31, 2019

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書
Consolidated Statements of Income by Business Group (Summary)

2. 宝酒造
Takara Shuzo

要約損益計算書
Statements of Income (Summary)

3. 宝酒造インターナショナルグループ
Takara Shuzo International Group

要約損益計算書
Statements of Income (Summary)

4. タカラバイオグループ
Takara Bio Group

要約損益計算書
Statements of Income (Summary)

5. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group

6. 2020年3月期第3四半期　参考資料
Reference Data for the Third Quarter Ended December 31, 2019

7. 2020年3月期　連結業績予想数値の修正
Revision of Consolidated Business Results Forecast for the Year Ending March 31, 2020

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

IR部 Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5194
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　IR部

Takara Holdings Inc. Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5194

E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 Consolidated Statements of Income by Business Group (Summary)

(百万円 Millions of Yen)

	2019年3月期 第3四半期累計	2020年3月期 第3四半期累計 Apr. 1, 2019 - Dec. 31, 2019		
	実績(a) FY2019(1Q-3Q) Actual (a)	実績(b) FY2020(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
宝酒造 Takara Shuzo	119,001	118,897	△ 103	99.9%
宝酒造インターナショナルグループ Takara Shuzo International Group	56,843	60,461	3,617	106.4%
タカラバイオ グループ Takara Bio Group	25,888	24,558	△ 1,329	94.9%
その他 Other	25,593	24,644	△ 948	96.3%
調整額 Adjustment	△ 16,703	△ 16,389	314	―
売上高 Net sales	210,622	212,172	1,550	100.7%
売上原価 Cost of sales	127,706	130,168	2,461	101.9%
売上総利益 Gross profit	82,915	82,004	△ 911	98.9%
運送費、保管料 Transportation and storage	7,823	8,334	510	106.5%
広告宣伝費 Advertising	2,289	1,645	△ 643	71.9%
販売促進費 Sales promotion	25,131	26,071	940	103.7%
研究開発費 Research and development	3,444	3,112	△ 331	90.4%
管理費、その他 Other, net	29,210	30,002	792	102.7%
販売費及び一般管理費 SG&A expenses	67,900	69,167	1,267	101.9%
宝酒造 Takara Shuzo	6,683	4,983	△ 1,699	74.6%
宝酒造インターナショナルグループ Takara Shuzo International Group	3,230	2,313	△ 917	71.6%
タカラバイオ グループ Takara Bio Group	3,432	3,879	446	113.0%
その他 Other	1,651	1,716	65	103.9%
調整額 Adjustment	18	△ 56	△ 74	―
営業利益(△:損失) Operating income(Δ:loss)	15,015	12,836	△ 2,179	85.5%
受取利息・配当金 Interest and Dividends income	691	788	96	113.9%
その他営業外収益 Other, net	373	495	121	132.6%
営業外収益 Non-operating income	1,065	1,283	218	120.5%
支払利息 Interest and discounts expenses	276	303	27	109.9%
その他営業外費用 Other, net	384	525	141	136.7%
営業外費用 Non-operating expenses	661	829	168	125.5%
経常利益(△:損失) Ordinary income(Δ:loss)	15,420	13,290	△ 2,129	86.2%
特別利益 Extraordinary income	81	1,294	1,213	1592.1%
特別損失 Extraordinary loss	1,075	787	△ 287	73.3%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	14,426	13,797	△ 628	95.6%
法人税、住民税及び事業税 Current income taxes	4,627	4,019	△ 607	86.9%
法人税等調整額 Deferred income taxes	△ 310	305	615	―
四半期純利益(△:損失) Net income(Δ:loss)	10,110	9,473	△ 637	93.7%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	1,157	1,172	14	101.3%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	8,952	8,300	△ 651	92.7%
設備投資額(有形・無形) Capital expenditures	5,156	10,635	5,479	206.3%
減価償却費(有形・無形) Depreciation and Amortization	4,813	5,310	496	110.3%
のれん償却額 Amortization of goodwill	646	629	△ 17	97.3%

営業外収益 Non-operating income	受取利息202、受取配当金585 など Interest income 202, Dividends income 585, etc.
営業外費用 Non-operating expenses	支払利息177、社債利息125、為替差損209 など Interest expense 177, Interest on bonds 125, Foreign exchange losses 209 etc.
特別利益 Extraordinary income	投資有価証券売却益 1,130 など Gain on sales of investment securities 1,130 etc.
特別損失 Extraordinary loss	固定資産除売却損 233 など Loss on sales and retirement of non-current assets 233 etc.

2. 宝酒造 :Takara Shuzo

要約損益計算書 Statements of Income (Summary)

	2019年3月期 第3四半期累計	2020年3月期 第3四半期累計 Apr. 1, 2019 - Dec. 31, 2019		
	実績(a) FY2019(1Q-3Q) Actual (a)	実績(b) FY2020(1Q-3Q) Actual (b)	増減(b−a) Change (b-a)	比(b/a) YOY% (b/a)
焼酎 Shochu	41,186	38,026	△ 3,159	92.3%
清酒 Sake	17,524	16,860	△ 664	96.2%
ソフトアルコール飲料 Light-alcohol refreshers	29,742	32,603	2,860	109.6%
その他酒類 Other liquors	5,051	4,970	△ 81	98.4%
本みりん Hon Mirin	11,032	11,238	206	101.9%
その他調味料 Other seasonings	7,779	8,222	442	105.7%
原料用アルコール等 Raw alcohol	6,683	6,975	292	104.4%
売上高 Net sales	119,001	118,897	△ 103	99.9%
売上原価 Cost of sales	70,919	71,578	659	100.9%
売上総利益 Gross profit	48,081	47,318	△ 762	98.4%
運送費、保管料 Transportation and storage	5,867	6,286	418	107.1%
広告宣伝費 Advertising	1,981	1,524	△ 457	76.9%
販売促進費 Sales promotion	24,148	25,184	1,035	104.3%
研究開発費 Research and development	275	295	20	107.5%
管理費、その他 Other, net	9,124	9,044	△ 80	99.1%
販売費及び一般管理費 SG&A expenses	41,397	42,334	936	102.3%
営業利益(△:損失) Operating income(Δ:loss)	6,683	4,983	△ 1,699	74.6%
営業外収益 Non-operating income	749	288	△ 460	38.6%
営業外費用 Non-operating expenses	245	274	29	111.9%
経常利益(△:損失) Ordinary income(Δ:loss)	7,187	4,998	△ 2,188	69.5%
特別利益 Extraordinary income	2	124	121	4149.9%
特別損失 Extraordinary loss	42	260	218	618.3%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	7,147	4,861	△ 2,285	68.0%
法人税、住民税及び事業税 Current income taxes	2,097	1,431	△ 665	68.3%
法人税等調整額 Deferred income taxes	35	141	105	393.5%
四半期純利益(△:損失) Net income(Δ:loss)	5,014	3,288	△ 1,725	65.6%
設備投資額(有形・無形) Capital expenditures	1,019	4,616	3,596	452.6%
減価償却費(有形・無形) Depreciation and Amortization	1,647	1,934	286	117.4%

3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 Statements of Income (Summary)

	2019年3月期 第3四半期累計	2020年3月期 第3四半期累計 Apr. 1, 2019 - Dec. 31, 2019		
	実績(a) FY2019(1Q-3Q) Actual (a)	実績(b) FY2020(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
海外酒類事業 Overseas Alcoholic beverages business	7,616	8,010	394	105.2%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	50,591	53,881	3,290	106.5%
その他 Other	48	190	142	393.6%
連結消去 Elimination	△ 1,413	△ 1,622	△ 208	―
売上高 Net sales	56,843	60,461	3,617	106.4%
売上原価 Cost of sales	40,196	43,194	2,998	107.5%
売上総利益 Gross profit	16,647	17,266	619	103.7%
運送費、保管料 Transportation and storage	1,623	1,965	341	121.1%
広告宣伝費 Advertising	79	63	△ 15	80.5%
販売促進費 Sales promotion	482	537	54	111.3%
管理費、その他 Other, net	11,231	12,387	1,155	110.3%
販売費及び一般管理費 SG&A expenses	13,416	14,953	1,536	111.5%
海外酒類事業 Overseas Alcoholic beverages business	1,344	1,534	189	114.1%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	2,939	1,962	△ 977	66.8%
その他 Other	△ 707	△ 627	79	―
連結消去 Elimination	△ 347	△ 556	△ 209	―
営業利益(△:損失) Operating income(Δ:loss)	3,230	2,313	△ 917	71.6%
営業外収益 Non-operating income	168	245	77	145.7%
営業外費用 Non-operating expenses	287	251	△ 35	87.6%
経常利益(△:損失) Ordinary income(Δ:loss)	3,111	2,307	△ 804	74.2%
特別利益 Extraordinary income	0	39	39	12051.7%
特別損失 Extraordinary loss	10	13	2	124.3%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	3,101	2,333	△ 767	75.2%
法人税、住民税及び事業税 Current income taxes	916	708	△ 207	77.4%
法人税等調整額 Deferred income taxes	11	24	12	207.8%
四半期純利益(△:損失) Net income(Δ:loss)	2,173	1,600	△ 572	73.6%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	333	104	△ 228	31.4%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	1,840	1,496	△ 343	81.3%
設備投資額(有形・無形) Capital expenditures	832	1,436	603	172.4%
減価償却費(有形・無形) Depreciation and Amortization	748	874	126	116.9%
のれん償却額 Amortization of goodwill	272	256	△ 16	94.1%

4. タカラバイオグループ :Takara Bio Group

要約損益計算書 Statements of Income (Summary)

	2019年3月期 第3四半期累計	2020年3月期 第3四半期累計 Apr. 1, 2019 - Dec. 31, 2019		
	実績(a) FY2019(1Q-3Q) Actual (a)	実績(b) FY2020(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
研究用試薬 Research reagents	17,093	17,750	657	103.8%
理化学機器 Scientific instruments	1,907	952	△ 955	49.9%
受託・その他 Contracted service and other	2,983	3,684	701	123.5%
バイオ産業支援　計 Bioindustry	21,984	22,388	403	101.8%
遺伝子医療 Gene Therapy	2,304	2,170	△ 134	94.2%
その他 Other	1,599	―	△ 1,599	―
売上高 Net sales	25,888	24,558	△ 1,329	94.9%
売上原価 Cost of sales	10,947	9,767	△ 1,180	89.2%
売上総利益 Gross profit	14,940	14,791	△ 149	99.0%
運送費、保管料 Transportation and storage	514	332	△ 182	64.6%
広告宣伝費 Advertising	38	52	14	136.3%
販売促進費 Sales promotion	544	434	△ 109	79.8%
研究開発費 Research and development	3,164	2,812	△ 352	88.9%
管理費、その他 Other, net	7,244	7,279	34	100.5%
販売費及び一般管理費 SG&A expenses	11,507	10,911	△ 595	94.8%
バイオ産業支援 Bioindustry	4,138	4,465	327	107.9%
遺伝子医療 Gene Therapy	885	1,077	191	121.6%
その他 Other	△ 3	―	3	―
共通 Eliminations/Corporate	△ 1,587	△ 1,663	△ 76	―
営業利益(△:損失) Operating income(Δ:loss)	3,432	3,879	446	113.0%
営業外収益 Non-operating income	201	212	11	105.6%
営業外費用 Non-operating expenses	84	195	111	231.4%
経常利益(△:損失) Ordinary income(Δ:loss)	3,549	3,896	346	109.8%
特別利益 Extraordinary income	55	0	△ 54	0.9%
特別損失 Extraordinary loss	900	13	△ 886	1.5%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	2,703	3,883	1,179	143.6%
法人税、住民税及び事業税 Current income taxes	1,107	935	△ 171	84.5%
法人税等調整額 Deferred income taxes	△ 494	229	724	―
四半期純利益(△:損失) Net income(Δ:loss)	2,091	2,717	625	129.9%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	3	8	5	291.2%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	2,088	2,708	619	129.7%
設備投資額(有形・無形) Capital expenditures	3,124	4,167	1,042	133.4%
減価償却費(有形・無形) Depreciation and Amortization	2,014	2,102	88	104.4%
のれん償却額 Amortization of goodwill	374	372	△ 1	99.6%

5. 6年間の財務サマリー(グループ別) :Six-Year Financial Summary by Business Group

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

		2015年3月期 第3四半期 FY2015(1Q-3Q)	2016年3月期 第3四半期 FY2016(1Q-3Q)	2017年3月期 第3四半期 FY2017(1Q-3Q)	2018年3月期 第3四半期 FY2018(1Q-3Q)	2019年3月期 第3四半期 FY2019(1Q-3Q)	2020年3月期 第3四半期 FY2020(1Q-3Q)	前期対比 Change from FY2019(1Q-3Q) 増減 Change	前期対比 Change from FY2019(1Q-3Q) 比 YOY%
売上高	Net sales	166,054	170,250	172,218	204,266	210,622	212,172	1,550	100.7%
売上原価	Cost of sales	100,975	102,349	101,336	124,486	127,706	130,168	2,461	101.9%
(売上高原価率)	(Ratio to Net sales)	60.8%	60.1%	58.8%	60.9%	60.6%	61.4%	+0.7pt	–
売上総利益	Gross profit	65,078	67,901	70,881	79,779	82,915	82,004	△ 911	98.9%
販売費及び一般管理費	SG&A expenses	54,497	57,809	58,139	66,175	67,900	69,167	1,267	101.9%
(売上高販管費率)	(Ratio to Net sales)	32.8%	34.0%	33.8%	32.4%	32.2%	32.6%	+0.4pt	–
営業利益(△:損失)	Operating income(Δ:loss)	10,580	10,091	12,741	13,604	15,015	12,836	△ 2,179	85.5%
(売上高営業利益率)	(Ratio to Net Sales)	6.4%	5.9%	7.4%	6.7%	7.1%	6.1%	-1.1pt	–
販売促進費	Sales promotion	23,957	24,561	25,020	24,840	25,131	26,071	940	103.7%
(売上高販促費率)	(Ratio to Net sales)	14.4%	14.4%	14.5%	12.2%	11.9%	12.3%	+0.4pt	–
研究開発費	R&D expenses	2,485	3,363	3,155	3,726	3,444	3,112	△ 331	90.4%
(売上高研究開発費率)	(Ratio to Net sales)	1.5%	2.0%	1.8%	1.8%	1.6%	1.5%	-0.2pt	–
設備投資額(有形・無形)	Capital expenditures	6,904	3,768	3,749	3,738	5,156	10,635	5,479	206.3%
減価償却費(有形・無形)	Depreciation and Amortization	3,358	3,820	3,753	4,767	4,813	5,310	496	110.3%
のれん償却額	Amortization of goodwill	350	404	349	625	646	629	△ 17	97.3%

宝酒造 :Takara Shuzo

(百万円 :Millions of Yen)

		2015年3月期 第3四半期 FY2015(1Q-3Q)	2016年3月期 第3四半期 FY2016(1Q-3Q)	2017年3月期 第3四半期 FY2017(1Q-3Q)	2018年3月期 第3四半期 FY2018(1Q-3Q)	2019年3月期 第3四半期 FY2019(1Q-3Q)	2020年3月期 第3四半期 FY2020(1Q-3Q)	前期対比 Change from FY2019(1Q-3Q) 増減 Change	前期対比 Change from FY2019(1Q-3Q) 比 YOY%
売上高	Net sales	–	–	116,025	117,845	119,001	118,897	△ 103	99.9%
売上原価	Cost of sales	–	–	68,731	70,038	70,919	71,578	659	100.9%
(売上高原価率)	(Ratio to Net sales)	–	–	59.2%	59.4%	59.6%	60.2%	+0.6pt	–
売上総利益	Gross profit	–	–	47,293	47,806	48,081	47,318	△ 762	98.4%
販売費及び一般管理費	SG&A expenses	–	–	41,112	41,108	41,397	42,334	936	102.3%
(売上高販管費率)	(Ratio to Net sales)	–	–	35.4%	34.9%	34.8%	35.6%	+0.8pt	–
営業利益(△:損失)	Operating income(Δ:loss)	–	–	6,181	6,698	6,683	4,983	△ 1,699	74.6%
(売上高営業利益率)	(Ratio to Net sales)	–	–	5.3%	5.7%	5.6%	4.2%	-1.4pt	–
販売促進費	Sales promotion	–	–	24,054	23,864	24,148	25,184	1,035	104.3%
(売上高販促費率)	(Ratio to Net sales)	–	–	20.7%	20.3%	20.3%	21.2%	+0.9pt	–
設備投資額(有形・無形)	Capital expenditures	–	–	1,094	1,348	1,019	4,616	3,596	452.6%
減価償却費(有形・無形)	Depreciation and Amortization	–	–	1,607	1,626	1,647	1,934	286	117.4%

2018年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円 :Millions of Yen)

		2015年3月期 第3四半期 FY2015(1Q-3Q)	2016年3月期 第3四半期 FY2016(1Q-3Q)	2017年3月期 第3四半期 FY2017(1Q-3Q)	2018年3月期 第3四半期 FY2018(1Q-3Q)	2019年3月期 第3四半期 FY2019(1Q-3Q)	2020年3月期 第3四半期 FY2020(1Q-3Q)	前期対比 Change from FY2019(1Q-3Q) 増減 Change	前期対比 Change from FY2019(1Q-3Q) 比 YOY%
売上高	Net sales	–	–	22,021	51,364	56,843	60,461	3,617	106.4%
売上原価	Cost of sales	–	–	14,801	36,170	40,196	43,194	2,998	107.5%
(売上高原価率)	(Ratio to Net sales)	–	–	67.2%	70.4%	70.7%	71.4%	+0.7pt	–
売上総利益	Gross profit	–	–	7,220	15,194	16,647	17,266	619	103.7%
販売費及び一般管理費	SG&A expenses	–	–	5,264	11,988	13,416	14,953	1,536	111.5%
(売上高販管費率)	(Ratio to Net sales)	–	–	23.9%	23.3%	23.6%	24.7%	+1.1pt	–
営業利益(△:損失)	Operating income(Δ:loss)	–	–	1,955	3,206	3,230	2,313	△ 917	71.6%
(売上高営業利益率)	(Ratio to Net sales)	–	–	8.9%	6.2%	5.7%	3.8%	-1.9pt	–
のれん償却後営業利益(△:損失)	Operating income after amortization of goodwill	–	–	1,727	2,944	2,957	2,056	△ 900	69.5%
(のれん償却後営業利益率)	(Ratio to Net sales)	–	–	7.8%	5.7%	5.2%	3.4%	-1.8pt	–
設備投資額(有形・無形)	Capital expenditures	–	–	404	1,130	832	1,436	603	172.4%
減価償却費(有形・無形)	Depreciation and Amortization	–	–	417	698	748	874	126	116.9%
のれん償却額	Amortization of goodwill	–	–	227	261	272	256	△ 16	94.1%

2018年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

		2015年3月期 第3四半期 FY2015(1Q-3Q)	2016年3月期 第3四半期 FY2016(1Q-3Q)	2017年3月期 第3四半期 FY2017(1Q-3Q)	2018年3月期 第3四半期 FY2018(1Q-3Q)	2019年3月期 第3四半期 FY2019(1Q-3Q)	2020年3月期 第3四半期 FY2020(1Q-3Q)	前期対比 Change from FY2019(1Q-3Q) 増減 Change	前期対比 Change from FY2019(1Q-3Q) 比 YOY%
売上高	Net sales	17,293	20,706	20,645	22,646	25,888	24,558	△ 1,329	94.9%
売上原価	Cost of sales	7,839	9,199	8,106	9,879	10,947	9,767	△ 1,180	89.2%
(売上高原価率)	(Ratio to Net sales)	45.3%	44.4%	39.3%	43.6%	42.3%	39.8%	-2.5pt	–
売上総利益	Gross profit	9,453	11,507	12,538	12,766	14,940	14,791	△ 149	99.0%
販売費及び一般管理費	SG&A expenses	8,190	10,062	9,813	11,157	11,507	10,911	△ 595	94.8%
(売上高販管費率)	(Ratio to Net sales)	47.4%	48.6%	47.5%	49.3%	44.5%	44.4%	-0.0pt	–
営業利益(△:損失)	Operating income(Δ:loss)	1,263	1,444	2,724	1,608	3,432	3,879	446	113.0%
(売上高営業利益率)	(Ratio to Net sales)	7.3%	7.0%	13.2%	7.1%	13.3%	15.8%	+2.5pt	–
研究開発費	R&D expenses	2,225	3,118	2,870	3,417	3,164	2,812	△ 352	88.9%
(売上高研究開発費率)	(Ratio to Net sales)	12.9%	15.1%	13.9%	15.1%	12.2%	11.5%	-0.8pt	–
設備投資額(有形・無形)	Capital expenditures	3,380	1,850	1,200	910	3,124	4,167	1,042	133.4%
減価償却費(有形・無形)	Depreciation and Amortization	956	1,247	1,276	1,896	2,014	2,102	88	104.4%
のれん償却額	Amortization of goodwill	92	135	121	364	374	372	△ 1	99.6%

6. 2020年3月期第3四半期 参考資料 :Reference Data for the Third Quarter Ended December 31, 2019

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	2019年3月期 第3四半期累計	2020年3月期 第3四半期累計 Apr. 1, 2019 - Dec. 31, 2019	
	実績(a) FY2019(1Q-3Q) Actual (a)	実績(b) FY2020(1Q-3Q) Actual (b)	前期差 Change(c-a)
米ドル : US dollar	109.61	109.13	△ 0.48
ポンド: Pound	148.11	138.95	△ 9.16
ユーロ: Euro	130.87	122.62	△ 8.25
人民元: Yuan	16.84	15.89	△ 0.95
100ウォン: 100 Won	10.05	9.40	△ 0.65
インドルピー: Rupee	1.64	1.56	△ 0.08
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	12.79	11.61	△ 1.18
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	81.78	79.99	△ 1.79
ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar	83.06	76.31	△ 6.75

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2019(1Q-3Q)
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	△ 2,506
うち宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Net sales of Takara Shuzo International Group	△ 1,992
海外酒類事業 Overseas Alcoholic beverages business	△ 186
海外日本食材卸事業 Japanese food wholesale business in overseas markets	△ 1,813
その他 Other	—
連結消去 Elimination	6
うちタカラバイオグループ Net sales of Takara Bio Group	△ 521
研究用試薬 Research reagents	△ 477
理化学機器 Scientific instruments	△ 16
受託・その他 Contracted service and other	△ 27
バイオ産業支援 計 Bioindustry	△ 521
遺伝子医療 Gene Therapy	—
その他 Other	—

② 海外売上高比率 :Overseas sales ratio

(百万円 :Millions of Yen)

	2019年3月期第3四半期 実績 FY2019(1Q-3Q) Actual			2020年3月期第3四半期 実績 FY2020(1Q-3Q) Actual		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	119,001	—	—	118,897	—	—
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group	56,843	56,582	99.5%	60,461	60,137	99.5%
タカラバイオグループ Takara Bio Group	25,888	14,586	56.3%	24,558	14,665	59.7%
その他および調整額 Other / Adjustment	8,889	—	—	8,255	—	—
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	210,622	71,168	33.8%	212,172	74,803	35.3%

③ 海外主要子会社の業績 :Financial Forecast of major overseas subsidiaries

		2019年3月期第3四半期 実績 FY2019(1Q-3Q) Actual		2020年3月期第3四半期 実績 FY2020(1Q-3Q) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	24,470	2,048	25,930	2,433
Takara Sake USA Inc.	百 万 円 :Millions of Yen	2,682	224	2,829	265
宝酒造食品	千 元 :Thousands of Yuan	38,352	2,314	38,200	2,055
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	645	38	607	32
トマーチン	千 ポ ン ド :Thousands of Pound	12,811	3,405	13,739	3,381
The Tomatin Distillery Co.,Ltd.	百 万 円 :Millions of Yen	1,897	504	1,909	469
ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ドル :Thousands of US dollar	16,209	6,723	18,508	8,278
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	1,776	736	2,019	903
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	118,161	12,661	132,115	12,195
FOODEX Group	百 万 円 :Millions of Yen	15,463	1,656	16,200	1,495
タザキフーズ	千 ポ ン ド :Thousands of Pound	29,443	2,049	33,754	1,165
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	4,360	303	4,690	161
ミューチャルトレーディング	千 US ドル :Thousands of US dollar	250,196	9,218	273,307	4,194
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	27,424	1,010	29,826	457
ニッポンフード	千 AUS ドル :Thousands of Australian dollar	40,243	Δ 373	41,480	Δ 1,992
Nippon Food Supplies Company Pty Ltd	百 万 円 :Millions of Yen	3,342	Δ 31	3,165	Δ 152
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S. (連結)	千 ユ ー ロ :Thousands of Euro	17,723	968	18,790	600
Takara Bio Europe S.A.S. Consolidated	百 万 円 :Millions of Yen	2,319	126	2,304	73
宝生物工程(大連)	千 元 :Thousands of Yuan	171,117	39,327	154,543	45,445
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	2,881	662	2,455	722
宝日医生物技術(北京)	千 元 :Thousands of Yuan	263,935	47,111	291,921	57,363
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	4,444	793	4,638	911
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	7,558	1,233	8,100	1,254
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	759	123	761	117
タカラバイオDSSインド	千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	146,232	2,829	173,217	14,468
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	239	4	270	22
タカラバイオUSA	千 US ドル :Thousands of US dollar	73,958	8,655	73,491	8,242
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	8,106	948	8,020	899

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

(百万円 :Millions of Yen)

	対前期増減 Change from FY2019(1Q-3Q)		
	増減計 Total Change	数量差 Change in quantities	単価差 Change in unit price
売上総利益 計 Gross profit	Δ 762	Δ 246	Δ 516
(主な内訳)			
焼酎 Shochu	Δ 1,293	Δ 1,233	Δ 60
清酒 Sake	Δ 478	Δ 294	Δ 184
ｿﾌﾄｱﾙｺｰﾙ飲料 Light-alcohol refreshers	+1,039	+1,048	Δ 9
本みりん Hon Mirin	Δ 5	+126	Δ 132
(参考)原価コストダウン Reference :Cost reduction	Δ 757	※上記数量差および単価差に含む *Included in changes above	

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結)要約損益計算書(p.1)における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.1)

	2019年3月期第3四半期 実績 FY2019(1Q-3Q) Actual		2020年3月期第3四半期 実績 FY2020(1Q-3Q) Actual	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	10,876	504	11,043	523
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	402	330	400	336
その他 Other	14,314	815	13,200	856
「その他」計 Total "Other"	25,593	1,651	24,644	1,716

7. 2020年3月期 連結業績予想数値の修正 :Revision of Consolidated Business Results Forecast for the Year Ending March 31, 2020

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	2019年3月期 FY2019	2020年3月期 FY2020_Apr. 1, 2019 - Mar. 31, 2020		対前期 Change from FY2019		対11/12予想 Change from forecast announced Nov. 2019	
	実績(a) Actual (a)	11/12予想(b) Forecast announced Nov. 2019 (b)	2/13予想(c) Forecast announced Feb. 2020 (c)	増減(c-a) Change (c-a)	比(c/a) % (c/a)	増減(c-b) Change (c-b)	比(c/b) % (c/b)
宝酒造 Takara Shuzo	152,457	157,787	153,074	616	100.4%	△ 4,713	97.0%
宝酒造インターナショナルグループ Takara Shuzo International Group	77,834	81,546	82,219	4,384	105.6%	673	100.8%
タカラバイオ グループ Takara Bio Group	35,841	33,900	34,300	△ 1,541	95.7%	400	101.2%
その他 Other	32,742	31,985	31,748	△ 994	97.0%	△ 237	99.3%
調整額 Adjustment	△ 21,431	△ 21,218	△ 21,341	90	―	△ 123	―
売上高 Net sales	277,443	284,000	280,000	2,556	100.9%	△ 4,000	98.6%
売上原価 Cost of sales	168,694	173,500	171,500	2,805	101.7%	△ 2,000	98.8%
売上総利益 Gross profit	108,749	110,500	108,500	△ 249	99.8%	△ 2,000	98.2%
運送費、保管料 Transportation and storage	10,162	11,000	10,900	737	107.3%	△ 100	99.1%
広告宣伝費 Advertising	2,755	2,000	2,000	△ 755	72.6%	―	100.0%
販売促進費 Sales promotion	34,012	35,500	35,400	1,387	104.1%	△ 100	99.7%
研究開発費 Research and development	4,708	4,400	4,400	△ 308	93.4%	―	100.0%
管理費、その他 Other, net	39,305	40,100	40,500	1,194	103.0%	400	101.0%
販売費及び一般管理費 SG&A expenses	90,945	93,000	93,200	2,254	102.5%	200	100.2%
宝酒造 Takara Shuzo	5,948	5,760	3,848	△ 2,100	64.7%	△ 1,912	66.8%
宝酒造インターナショナルグループ Takara Shuzo International Group	4,532	3,795	3,576	△ 956	78.9%	△ 219	94.2%
タカラバイオ グループ Takara Bio Group	5,463	6,200	6,200	736	113.5%	―	100.0%
その他 Other	1,954	2,043	2,035	80	104.1%	△ 8	99.6%
調整額 Adjustment	△ 95	△ 298	△ 359	△ 263	―	△ 60	―
営業利益(△:損失) Operating income(Δ:loss)	17,804	17,500	15,300	△ 2,504	85.9%	△ 2,200	87.4%
受取利息・配当金 Interest and Dividends income	800	800	800	△ 0	100.0%	―	100.0%
その他営業外収益 Other, net	660	600	600	△ 60	90.8%	―	100.0%
営業外収益 Non-operating income	1,461	1,400	1,400	△ 61	95.8%	―	100.0%
支払利息 Interest and discounts expenses	387	400	400	12	103.3%	―	100.0%
その他営業外費用 Other, net	518	500	600	81	115.7%	100	120.0%
営業外費用 Non-operating expenses	905	900	1,000	94	110.4%	100	111.1%
経常利益(△:損失) Ordinary income(Δ:loss)	18,359	18,000	15,700	△ 2,659	85.5%	△ 2,300	87.2%
特別利益 Extraordinary income	696	800	1,200	503	172.2%	400	150.0%
特別損失 Extraordinary loss	1,397	1,100	1,500	102	107.3%	400	136.4%
税金等調整前当期純利益(△:損失) Income before income taxes(Δ:loss)	17,658	17,700	15,400	△ 2,258	87.2%	△ 2,300	87.0%
法人税、住民税及び事業税 Current income taxes	5,443	5,400	5,200	△ 110	97.9%	△ 200	96.3%
法人税等調整額 Deferred income taxes	△ 132						
当期純利益(△:損失) Net income(Δ:loss)	12,347	12,300	10,200	△ 2,147	82.6%	△ 2,100	82.9%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	1,936	1,900	1,600	△ 336	82.6%	△ 300	84.2%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	10,411	10,400	8,600	△ 1,811	82.6%	△ 1,800	82.7%
設備投資額(有形・無形) Capital expenditures	10,671	15,670	15,670	4,998	146.8%	―	100.0%
減価償却費(有形・無形) Depreciation and Amortization	6,490	7,400	7,350	859	113.2%	△ 50	99.3%
のれん償却額 Amortization of goodwill	865	830	830	△ 35	95.9%	―	100.0%